Skip to Content

Notice

Product-Specific Bioequivalence Recommendations; Draft and Revised Draft Guidances for Industry; Availability

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Notice.

SUMMARY:

The Food and Drug Administration (FDA or the Agency) is announcing the availability of additional draft and revised draft product-specific bioequivalence (BE) recommendations. The recommendations provide product-specific guidance on the design of BE studies to support abbreviated new drug applications (ANDAs). In the Federal Register of June 11, 2010, FDA announced the availability of a guidance for industry entitled “Bioequivalence Recommendations for Specific Products,” which explained the process that would be used to make product-specific BE recommendations available to the public on FDA's Web site. The BE recommendations identified in this notice were developed using the process described in that guidance.

DATES:

Although you can comment on any guidance at any time (see 21 CFR Start Printed Page 1250310.115(g)(5)), to ensure that the Agency considers your comments on these draft and revised draft guidances before it begins work on the final versions of the guidances, submit either electronic or written comments on the draft and revised draft product-specific BE recommendations listed in this notice by May 8, 2015.

ADDRESSES:

Submit written requests for single copies of the individual BE guidances to the Division of Drug Information, Center for Drug Evaluation and Research, Food and Drug Administration, 10001 New Hampshire Ave., Hillandale Building, 4th Floor, Silver Spring, MD 20993-0002. Send one self-addressed adhesive label to assist that office in processing your requests. See the SUPPLEMENTARY INFORMATION section for electronic access to the draft guidance recommendations.

Submit electronic comments on the draft product-specific BE recommendations to http://www.regulations.gov. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

Xiaoqiu Tang, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 75, Rm. 4730, Silver Spring, MD 20993-0002, 301-796-5850.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

I. Background

In the Federal Register of June 11, 2010 (75 FR 33311), FDA announced the availability of a guidance for industry entitled “Bioequivalence Recommendations for Specific Products,” which explained the process that would be used to make product-specific BE recommendations available to the public on FDA's Web site at http://www.fda.gov/​Drugs/​GuidanceComplianceRegulatoryInformation/​Guidances/​default.htm.

As described in that guidance, FDA adopted this process as a means to develop and disseminate product-specific BE recommendations and provide a meaningful opportunity for the public to consider and comment on those recommendations. Under that process, draft recommendations are posted on FDA's Web site and announced periodically in the Federal Register. The public is encouraged to submit comments on those recommendations within 60 days of their announcement in the Federal Register. FDA considers any comments received, and either publishes final recommendations or publishes revised draft recommendations for comment. Recommendations were last announced in the Federal Register on December 30, 2014 (79 FR 78447). This notice announces draft product-specific recommendations, either new or revised, that are posted on FDA's Web site.

II. Drug Products for Which New Draft Product-Specific BE Recommendations Are Available

FDA is announcing the availability of a new draft guidance for industry on product-specific BE recommendations for drug products containing the following active ingredients:

Table 1—New Draft Product-Specific BE Recommendations for Drug Products

AAvanafil.
Azilsartan medoxomil; Chlorthalidone.
BBuprenorphine hydrochloride; Naloxone hydrochloride.
CChlorpheniramine maleate; Ibuprofen; Phenylephrine hydrochloride.
Cyclosporine (multiple reference listed drugs).
DDeferiprone.
Desoximetasone.
Diclofenac.
Dorzolamide.
Doxepin hydrochloride.
EEltrombopag olamine.
Emtricitabine; Rilpivirine hydrochloride; Tenofovir disoproxil fumarate.
FFlucinolone acetonide; Hydroquinone; Tretinoin.
IIbrutinib.
Ibuprofen.
Ipratropium bromide.
Isosorbide dinitrate.
Isotretinoin.
Ivacaftor.
LLoperamide hydrochloride (multiple reference listed drugs and dosage forms).
MMinocycline hydrochloride.
NNaproxen sodium; Diphenhydramine hydrochloride.
OOseltamivir phosphate.
Oxybutynin chloride.
PPotassium chloride.
Praziquantel.
Pyrimethamine.
SSodium polystyrene sulfonate
Spinosad.
Sucroferric oxyhydroxide.
TTicagrelor.
Topiramate (multiple reference listed drugs).
VVigabatrin.

III. Drug Products for Which Revised Draft Product-Specific BE Recommendations Are Available

FDA is announcing the availability of a revised draft guidance for industry on product-specific BE recommendations for drug products containing the following active ingredients:

Table 2—Revised Draft Product-Specific BE Recommendations for Drug Products

BBrimonidine tartrate (multiple reference listed drugs).
Brimonidine tartrate; Brinzolamide.
Brinzolamide.
Budesonide.
CCarbamazepine (multiple reference listed drugs and dosage forms).
Ciprofloxacin; dexamethasone.
DDexmethylphenidate hydrochloride.
Dextroamphetamine sulfate.
Doxepin hydrochloride.
GGabapentin.
IIsotretinoin.
MMethylphenidate hydrochloride.
Mirtazapine.
NNisoldipine.
PPaliperidone.
TTeriflunomide.

For a complete history of previously published Federal Register notices related to product-specific BE recommendations, go to http://www.regulations.gov and enter Docket No. FDA-2007-D-0369.

These draft and revised draft guidances are being issued consistent with FDA's good guidance practices regulation (21 CFR 10.115). These guidances represent the Agency's current thinking on product-specific design of BE studies to support ANDAs. They do not create or confer any rights for or on any person and do not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statutes and regulations.

IV. Comments

Interested persons may submit either electronic comments on any of the specific BE recommendations posted on FDA's Web site to http://www.regulations.gov or written comments to the Division of Dockets Management (see ADDRESSES). It is only necessary to send one set of comments. Identify comments with the docket number found in brackets in the heading of this document. The guidances, notices, and received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday, and Start Printed Page 12504will be posted to the docket at http://www.regulations.gov.

V. Electronic Access

Persons with access to the Internet may obtain the document at either http://www.fda.gov/​Drugs/​GuidanceComplianceRegulatoryInformation/​Guidances/​default.htm or http://www.regulations.gov.

Start Signature

Dated: March 3, 2015.

Leslie Kux,

Associate Commissioner for Policy.

End Signature End Supplemental Information

[FR Doc. 2015-05347 Filed 3-6-15; 8:45 am]

BILLING CODE 4164-01-P